E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
obese patients with non-alcoholic steatohepatitis (NASH) |
|
E.1.1.1 | Medical condition in easily understood language |
obese patients with fatty content in liver |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 22.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10053219 |
E.1.2 | Term | Non-alcoholic steatohepatitis |
E.1.2 | System Organ Class | 10019805 - Hepatobiliary disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the effect of LIK066 on alanine aminotransferase (ALT) after 12 weeks of treatment |
|
E.2.2 | Secondary objectives of the trial |
- To determine the effect of LIK066 on intrahepatic lipid after 12 weeks of treatment as measured by MRI
- To determine the effect of LIK066 on total body weight after 12 weeks of treatment
- To determine the effect of LIK066 on non-invasive markers of liver fibrosis after 12 weeks of treatment
- To determine the safety and tolerability of LIK066
- To evaluate the pharmacokinetics (PK) of LIK066 in NASH patients
- To determine the effect of LIK066 on aspartate aminotransferase (AST) after 12 weeks of treatment |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
EITHER
Histologic confirmed NASH based on liver biopsy obtained 2 years or less before randomization with a fibrosis level of F1, F2 or F3 in the absence of a histological diagnosis of alternative chronic liver disease AND ALT greater than or equal to 50 IU/L (males) or greater than or equal to 35 IU/L (females) at screening.
OR
Phenotypic diagnosis of NASH based on presence of ALL three of the following at screening:
-ALT greater than or equal to 50IU/L (males) or greater than or equal to 35 IU/L (females) AND
-BMI greater than or equal to 27 kg/m^2 (in patients with a self-identified race other than Asian) or greater than or equal
to 23 kg/m^2 (in patients with a self identified Asian race) AND
-Diagnosis of Type 2 diabetes mellitus by HbA1c: greater than or equal to 6.5 % and less than or equal to 10%.
Patients must weigh no more than 150 kg (330 lbs) to participate in the study.
Male and female patients 18 years or older at the time of screening visit. |
|
E.4 | Principal exclusion criteria |
- History or presence of other concomitant liver diseases.
- History or current diagnosis of ECG abnormalities.
- Use of GLP-1 agonists, SGLT2 inhibitors, TZDs, FXR agonists and any pharmacologically active weight loss drugs within 6 weeks of screening and until end of study.
- Patients with contraindications to MRI imaging.
- Current or history of significant alcohol consumption.
- Clinical evidence of hepatic decompensation or severe liver impairment.
- Women of child bearing potential (unless on basic contraception methods).
- Presence of liver cirrhosis. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change from baseline in ALT at week 12 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- Change from baseline in percent liver fat at week 12
- Change from baseline in total body weight at week 12
- Change from baseline on non-invasive liver fibrosis markers (Enhanced Liver Fibrosis (ELF) panel) at week 12
- Change from baseline in Aspartate aminotransferase (AST) at week 12
Pharmacokinetic End points:
- Observed maximum time duration of maximum concentration (Tmax) following drug administration
- Observed area under the curve up to the last measurable concentration (AUClast) following drug administration
- Observed maximum plasma concentration (Cmax) following drug administration
Safety and tolerability:
- Adverse events, safety laboratory tests including basic chemistry profile and liver biochemical tests |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Baseline, week 12
Pharmacokinetic end points : Day 56 (0, 1,2, 4 and 6 hrs post dose)
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
Hong Kong |
Israel |
Russian Federation |
Taiwan |
Thailand |
Turkey |
United States |
Netherlands |
Argentina |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |